Selective JAK2 Pseudokinase Ligands for Myeloproliferative Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies are inadequate for effectively treating myeloproliferative disorders such as chronic myelogenous leukemia, polycythemia vera, primary myelofibrosis, essential thrombocythemia, chronic neutrophilic leukemia, and chronic eosinophilic leukemia, as they often result in undesirable side effects and fail to selectively target the activating mutations in the JAK2 JH2 domain.
Innovation Solution
Development of specific compounds that selectively inhibit the JAK2 JH2 domain by binding to its ATP binding site with higher affinity than the JAK2 JH1 site, thereby reversing the activating effect of mutations like V617F, using a structure that includes a carbonyl group for hydrogen bonding and a secondary amide linkage for cation-π interaction with Lys581.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to treat myeloproliferative disorders, then treatment coverage is provided, but undesirable side effects occur and selective targeting of activating mutations is failed
Solution Approach 1:
The compound is designed to selectively inhibit the JAK2 JH2 domain with specific structural features (carbonyl group for hydrogen bonding, secondary amide linkage for cation-π interaction with Lys581) that target the unique properties of the mutant domain, achieving local specificity to reduce side effects while maintaining treatment effectiveness
Solution Approach 2:
The invention changes the binding affinity parameter by designing compounds that bind with higher affinity to the JAK2 JH2 domain compared to the JH1 site, thereby selectively reversing the activating effect of mutations like V617F while preserving wild-type kinase activity
2Measurement precision
If compounds bind to JAK2 JH2 domain with high affinity, then selective inhibition is achieved, but impact on wild-type JAK2 JH1 kinase activity must be minimized
Solution Approach 1:
The compound incorporates specific structural elements (carbonyl group positioned for hydrogen bonding, secondary amide linkage oriented for cation-π interaction with Lys581) that exploit local differences between the JH2 and JH1 domains, enabling selective binding to JH2 while preserving JH1 function
Solution Approach 2:
The compound acts as an intermediary that selectively binds to the JH2 domain to reverse its activating effect on JH1 kinase activity, rather than directly inhibiting JH1, thereby preserving wild-type kinase function while treating the pathological state
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds demonstrate strong binding affinity for the JAK2 JH2 domain, achieving selective inhibition with minimal impact on wild-type JAK2 JH1 kinase activity, thus offering a potential therapeutic approach for myeloproliferative neoplasms with reduced side effects.
Implementation Method 1
using a structure that includes a carbonyl group for hydrogen bonding
Implementation Method 2
a secondary amide linkage for cation-π interaction with Lys581
Data Source
AI summary
The compounds of Formula I described herein regulate activity of JAK2 by specifically binding to the JAK2 pseudokinase domain, JH2, and are useful as therapeutic agents in the treatment or amelioration of myeloproliferative disorders. Also provided herein are methods of treating myeloproliferative disorders, and methods of making compounds of Formula I.